Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications

Abstract

There is a gap of knowledge about the clinical and pathophysiological implications resulting from the interaction between primary hyperlipidemias and type 2 diabetes (T2D). Most of the existing evidence comes from sub-analyses of cohorts; scant information derives from randomized clinical trials. The expected clinical implications of T2D in patients with primary hyperlipidemias is an escalation of their already high cardiovascular risk. There is a need to accurately identify patients with this dual burden and to adequately prescribe lipid-lowering therapies, with the current advancements in newer therapeutic options. This review provides an update on the interactions of primary hyperlipidemias, such as familial combined hyperlipidemia, familial hypercholesterolemia, multifactorial chylomicronemia, lipoprotein (a), and type 2 diabetes.

Keywords: Combined hyperlipidemia; Diabetes; Diabetes complications; Diabetes incidence; Familial combined hyperlipidemia; Familial dysbetalipoproteinemia; Familial hypercholesterolemia; Interactions; Lp(a); Multifactorial chylomicronemia; Primary hyperlipidemias; Type 2 diabetes; Type III hyperlipidemia.